Graviton Bioscience
Samuel Waksal is the Chief Executive Officer at Graviton Bioscience, where the focus is on curing diseases through restored homeostasis. With a background in immunology from The Ohio State University College of Medicine, Samuel has founded and held various leadership positions in companies like Graviton Biopharmaceuticals Corporation, BRAIN-MIND INSTITUTE, and Appel Alzheimer's Research Institute. Samuel is dedicated to working in novel areas of signaling disorders of the immune system, the brain, and neurodegenerative diseases.
Graviton Bioscience
Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), along with other therapeutic compounds.